EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database ,

ISSN 2394-3211

Impact Factor: 6.222

ICV - 79.57

Abstract

BETULINIC ACID-MEDIATED CELL CYCLE ARREST, DECREASE IN MITOCHONDRIAL MEMBRANE POTENTIAL AND SUCCINATE DEHYDROGENASE ACTIVITY IN MURINE ASCITES DALTONÃ¢â‚¬â„¢S LYMPHOMA

Surya Bali Prasad*, Anamika Bhaumik, Javadi Monisha, Arun B. Gurung, Ajaikumar B. Kunnumakkara, Atanu Bhattacharjee and Rajesh Prasad

ABSTRACT

Betulinic acid is a pentacyclic triterpenoid originally isolated from the bark of the white birch Betula pubescens, from which it got its name. Betulinic acid exhibits cytotoxicity in several cancer cell lines and the antitumor potential of betulinic acid against murine ascites Dalton’s lymphoma has been earlier reported by us. Present studies were undertaken to further explore and evaluate the possible mechanism of antitumor activity of betulinic acid with reference to cell cycle analysis, changes in mitochondrial membrane potential and succinate dehydrogenase activity in Dalton’s lymphoma cells. Cell cycle analysis using flow cytometry, changes in mitochondrial membrane potential and succinate dehydrogenase activity in Dalton’s lymphoma cells were determined after betulinic aid treatment. In silico molecular docking study was done to scrutinize possible interaction of succinate dehydrogenase with betulinic acid. Betulinic acid treatment caused cell cycle arrest at S phase and also decreased mitochondrial membrane potential and succinate dehydrogenase activity in Dalton’s lymphoma cells. Molecular docking study revealed the strong binding affinity of betulinic acid with succinate dehydrogenase. The decreased mitochondrial membrane potential and inhibition in succinate dehydrogenase activity in Dalton’s lymphoma tumor cells after betulinic acid treatment may lead to the development of mitochondrial dysfunction and could be contributing to tumor cells death and should be imperative in its antitumor activity. It is suggested that mitochondria-targeted agents such as betulinic acid holds great promise as a novel anticancer drug.

Keywords: Betulinic acid, DaltonÃ¢â‚¬â„¢s lymphoma. cell cycle, mitochondrial membrane potential, succinate dehydrogenase.

[Full Text Article]

SJIF Impact Factor: 6.222

INDEXING

Indexing

LOGIN

NEWS & UPDATION

New Issue Published
Its Our pleasure to inform you that, EJPMR 1 September 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

EJPMR: SEPTEMBER ISSUE PUBLISHED
SEPTEMBER issue has been successfully launched on 1 SEPTEMBER 2023.

EJPMR New Impact Factor
Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from 5.804 to 6.222, due to high quality Publication at International Level